

This listing of claims will replace all prior versions, and listings, of claims in our amendments or responses to Office actions.

Listing of Claims:

1. (Currently amended) A method of treating a human subject experiencing a physiological disorder comprising administering an effective amount of an antagonist of antibody that specifically binds to DCRS5 (SEQ ID NO: 2), or antigen binding fragment thereof, wherein the antagonist is a binding composition derived from the antigen binding site of an antibody, or is a nucleic acid, wherein the disorder comprises:
 - a) rheumatoid arthritis;
 - b) asthma or allergy;
 - c) chronic obstructive pulmonary disorder (COPD);
 - d) an interstitial lung disorder;
 - e) an inflammatory bowel disorder (IBD); or
 - f) an inflammatory skin disorder.
2. (Withdrawn) The method of Claim 1, wherein the skin disorder is:
 - a) psoriasis; or
 - b) atopic dermatitis.
3. (Original) The method of Claim 1, wherein the IBD is:
 - a) Crohn's disease; or
 - b) ulcerative colitis.
4. (Withdrawn) The method of Claim 1, wherein the interstitial lung disorder is:
 - a) idiopathic pulmonary fibrosis;
 - b) eosinophilic granuloma; or
 - c) hypersensitivity pneumonitis.
5. (Cancelled)

6. (Currently amended) The method of ~~Claim 5~~ Claim 1, wherein the binding composition antagonist antibody or antigen binding fragment thereof comprises:

- a) a polyclonal antibody;
- b) a monoclonal antibody;
- c) a humanized antibody; or
- d) an Fab, Fv, or F(ab')₂ fragment.

7-17. (Cancelled)

18. (Withdrawn - New) The method of Claim 1, wherein the physiological disorder is rheumatoid arthritis.

19. (Withdrawn - New) The method of Claim 1, wherein the physiological disorder is asthma.

20. (Withdrawn - New) The method of Claim 1, wherein the physiological disorder is allergy.

21. (Withdrawn - New) The method of Claim 1, wherein the physiological disorder is chronic obstructive pulmonary disorder (COPD).

22. (New) The method of Claim 3, wherein the IBD is Crohn's disease.

23. (New) The method of Claim 3, wherein the IBD is ulcerative colitis.

24. (New) The method of Claim 6, wherein the antagonist antibody or antigen binding fragment thereof comprises a monoclonal antibody.

25. (New) The method of Claim 6, wherein the antagonist antibody or antigen binding fragment thereof comprises a humanized antibody.

26. (New) The method of Claim 6, wherein the antagonist antibody or antigen binding fragment thereof comprises an Fab, Fv, or F(ab')₂ fragment.